Greg Plunkett News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Putting Australian clinical research on the map globally, comes the ground-breaking first-in-human clinical trial for KIO-301. MELBOURNE, Australia, Feb. 15, 2023 /PRNewswire/ -- In collaboration with US-based Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) and The Royal Adelaide Hospital, leading Australian CRO, Accelagen, is proud to announce that dosing has commenced in the Phase 1 first-in-human trial for KIO-301. This trial represents a remarkable development in the treatment of people with the rare inherited condition, Retinitis Pigmentosa (RP), which currently has no approved cure or standar...

/PRNewswire/ -- In collaboration with US-based Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) and The Royal Adelaide Hospital, leading Australian CRO, Accelagen,...

EQS-News: Vakzine Projekt Management GmbH / Key word(s): Study results VPM oversees clinical trial and translational project management – Positive Phase I data of client Memo Therapeutics AG 25.01.2023 / 10:00 CET/CEST The issuer is solely responsible for the content of this announcement. VPM ov...

EQS-News: Vakzine Projekt Management GmbH / Key word(s): Study results VPM oversees clinical trial and translational project management - Positive Phase I data of client Memo Therapeutics

With over 110% revenue growth in the last two years, Accelagen announces move to new office space in Hawthorn East, Melbourne MELBOURNE, Australia, Sept. 20, 2022 /PRNewswire/ --Accelagen, one of Australia's leading Contract Research Organisations, has taken new 472sqMoffice space in Hawthorn East following two years of rapid growth for the business. Now a multi-million dollarbusiness built up from a small consultancy in 2010, Accelagen's team of experts across its key service offerings; Clinical Trial Management, Regulatory Affairs, Strategic Consultation and the newly launched Biomet...